Catalyst Wire Dossier Catalyst Wire Dossier

NEXLIZET

bempedoic acid and ezetimibe · Esperion Therapeutics, Inc.
Drug timelines are a Plus or Pro feature.

11 regulatory and trial events tracked for NEXLIZET, covering 2020-02-26 to 2026-03-20. Get the full timeline:

Most recent: Clinical Trial Update: Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia

See pricing